Health insurance company Humana (NYSE:HUM) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.4% year on year to $32.11 billion. The company’s full-year revenue guidance of $127 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $11.58 per share was 15% above analysts’ consensus estimates.
Is now the time to buy HUM? Find out in our full research report (it’s free).
-
Revenue: $32.11 billion vs analyst estimates of $32 billion (8.4% year-on-year growth, in line)
-
Adjusted EPS: $11.58 vs analyst estimates of $10.07 (15% beat)
-
Adjusted EBITDA: $2.25 billion vs analyst estimates of $1.92 billion (7% margin, 17.2% beat)
-
The company reconfirmed its revenue guidance for the full year of $127 billion at the midpoint
-
Management reiterated its full-year Adjusted EPS guidance of $16.25 at the midpoint
-
Operating Margin: 6.3%, up from 4.2% in the same quarter last year
-
Free Cash Flow Margin: 0.7%, similar to the same quarter last year
-
Customers: 14.84 million, down from 16.35 million in the previous quarter
-
Market Capitalization: $30.52 billion
Humana’s first quarter results for 2025 reflected operational progress, particularly in margin improvement and cost management, as management emphasized disciplined execution and strategic investments in the Medicare Advantage and CenterWell segments. CEO James Rechtin attributed the quarter’s performance to “progress on Stars, strong patient growth in primary care, and a focus on cost efficiency,” and noted that outperformance was partly due to the timing of expenses. CFO Celeste Mellet added that “the underlying fundamentals of the business, including membership and patient growth, revenue and medical cost trends, are developing as expected.”
Looking ahead, management reaffirmed its full-year guidance, citing ongoing investments in clinical quality, operating efficiencies, and the continued maturation of the Medicaid and CenterWell businesses. Rechtin stated, “We are executing against the things we control,” while Mellet highlighted priorities such as expanding margins, delivering industry-leading Stars results, and increasing balance sheet efficiency. However, leadership acknowledged that external factors—particularly the pending CMS Stars litigation and regulatory changes—continue to introduce uncertainty to the outlook.
Management’s remarks zeroed in on operational improvements, cost control, and strategic growth areas, with a particular focus on the evolving regulatory environment and the importance of Stars quality ratings for long-term profitability.
-
Margin Improvement Focus: Management attributed margin gains to a combination of operational efficiencies and expense timing, noting that some cost benefits in the quarter may not be durable throughout the year. Increased use of artificial intelligence in contact centers was cited as contributing to lower administrative costs.
-
Stars Quality Initiatives: CEO James Rechtin highlighted ongoing efforts to improve Stars ratings, including targeted home visits and virtual health campaigns aimed at closing care gaps. These initiatives are expected to reduce missed care by 25% year-over-year, directly impacting future revenue and margin opportunities.
-
Membership and Product Mix Shifts: Management described a strategic shift towards higher lifetime value members, with exits from less profitable plan segments. George Renaudin, President of Humana’s insurance segment, reported strong growth in key markets such as Florida, Illinois, and Texas, and emphasized that the business is prioritizing sustainable margin over membership growth.
-
Medicaid and CenterWell Expansion: The company reported robust patient and membership growth in Medicaid and primary care, driven by new center openings and contract wins, including an intent to award in Illinois for a dual eligible program. The CenterWell Pharmacy business is also expanding through new fulfillment agreements.
-
Regulatory and Industry Uncertainty: Leadership repeatedly cited the impact of CMS Stars litigation and regulatory changes on the long-term margin outlook, emphasizing that “timing is dictated by the legal system” and that management is focused on mitigating risks through diversification and operational control.
Management’s outlook for the remainder of 2025 centers on managing regulatory headwinds, maintaining margin discipline, and leveraging growth in value-based care segments amid ongoing industry change.
-
Regulatory and Litigation Risk: External factors, such as the pending outcome of CMS Stars litigation and evolving Medicare Advantage reimbursement models, remain the largest sources of uncertainty for both revenue and margin progression. Management stated that “the exact timing is tied to the outcome on Stars.”
-
Operational Efficiency Initiatives: The company is investing in process improvements and technology, including AI-driven tools in customer service, which are expected to support operating margin expansion while maintaining service quality.
-
Growth in Value-Based Businesses: Expansion of the CenterWell and Medicaid businesses, which management described as “maturing through their respective J curves,” is viewed as key to future earnings growth. Leadership highlighted the durability of recent pharmacy and primary care growth, although cautioned that some recent gains may be timing-related.
-
Sarah James (Cantor Fitzgerald): Asked about the timing of investments moving out of Q1 and whether the quarter met expectations. CFO Celeste Mellet clarified that most investments will impact later quarters, and Q1 results matched internal expectations aside from expense timing.
-
Ben Hendrix (RBC Capital Markets): Inquired about the path to achieving a 3% Medicare Advantage margin target and whether Stars litigation affects this goal. Management reiterated focus on the target, citing Stars outcomes as the key variable with no major changes to strategy.
-
Justin Lake (Wolfe Research): Sought updates on Stars progress and how bids will be handled if litigation timing remains uncertain. CEO James Rechtin said progress on Stars is positive but declined to speculate on outcomes, and George Renaudin discussed ongoing diversification efforts in bids.
-
Joanna Gajuk (Bank of America): Asked about drivers of CenterWell outperformance in the quarter. Mellet attributed a third of the beat to CenterWell, primarily from specialty pharmacy mix and higher patient growth, while noting some effects may not persist.
-
David Windley (Jefferies): Questioned the impact of exiting certain dual eligible contracts on margins and future membership strategy. Mellet and Rechtin said margin has improved due to strategic exits and that future growth will prioritize sustainable value over size.
In the upcoming quarters, the StockStory team will be closely monitoring (1) the resolution and impact of the CMS Stars litigation, which could significantly influence future margin trajectories; (2) the sustained performance and patient growth of the CenterWell and Medicaid businesses, especially as new centers come online and recent contract wins are integrated; and (3) the effectiveness of operating efficiency initiatives, such as increased AI deployment in customer service. The timing and durability of cost improvements will also be important for assessing management’s execution.
Humana currently trades at a forward P/E ratio of 16.9×. At this valuation, is it a buy or sell post earnings? See for yourself in our free research report.
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
